TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8694306
Drug: Remifentanil large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil large dose (1 microgram.kg‐1.min‐1)
Study: 21095484
Drug: Generic atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic atorvastatin 20 mg/d
Study: 21095484
Drug: Branded atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded atorvastatin 20 mg/d
Study: 15997937
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament injection with the Wand
Study: 15997937
Drug: Traditional syringe
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional syringe injection
Study: 9549398
Drug: Rest/postnitroglycerin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rest/postnitroglycerin (0.4 mg sublingually) technetium‐99m tetrofosmin SPET
Study: 19615915
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% bolus (20 ml) before rib spreading (pre-RS)
Study: 19615915
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% bolus (20 ml) after rib spreading (post-RS)
Study: 7983238
Drug: Sustained-release codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release codeine (SRC) 150 mg every 12 hours for 5 doses
Study: 7983238
Drug: Immediate-release codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release codeine phosphate (IRC) 60 mg (2 x 30 mg) every 4 hours for the first 3 doses, and 30 mg every 4 hours thereafter for 12 doses
Study: 7983238
Drug: Sustained-release codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release codeine (SRC)
Study: 7983238
Drug: Immediate-release codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release codeine phosphate (IRC)
Study: 2480613
Drug: Sulpiride (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (400, 800, or 1200 mg daily for 6 weeks)
Study: 11134500
Drug: Glycyl-L-tyrosine (graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyl-L-tyrosine (graded levels)
Study: 2368243
Drug: He‐Ne laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: He‐Ne laser therapy
Study: 28616929
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no He‐Ne laser therapy)
Study: 22011946
Drug: Medically supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medically supervised weight management (MSWM) program with monthly visits over 6 months
Study: 18614861
Drug: LPV/r in
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r in patients with HIV-1 RNA ≥ 100,000 copies/ml
Study: 8774159
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of high molecular weight hyaluronan
Study: 1730816
Drug: Progesterone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (400 mg/day, intravaginally)
Study: 6377712
Drug: co‐tetroxazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐tetroxazine (100 mg tetroxoprim and 250 mg sulphadiazine) b.i.d.
Study: 6377712
Drug: co‐trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) b.i.d.
Study: 29188338
Drug: Hypoglycaemia (PG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (PG 2.8 ± 0.2 mmol/l)
Study: 19644125
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for simple target phonemes
Study: 9785144
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg per day (initially 2.5 to 5 mg, increased to 10 mg in five patients)
Study: 2346543
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg acetylsalicylic acid (ASA) daily
Study: 2346543
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg paracetamol daily
Study: 11768838
Drug: Almotriptan 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 2 mg
Study: 10604044
Drug: Azelastine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine combination therapy (azelastine nasal spray 0.14 mg twice daily + azelastine tablet 2 mg at night)
Study: 10604044
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray only (after day five)
Study: 7723663
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (both groups)
Study: 1975162
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 micrograms twice a day
Study: 1975162
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 200 micrograms four times a day
Study: 28489877
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity (PA) intervention, including at least 1 hour/day of moderate PA and additional strenuous weekly activity, collective walks, and theoretical group sessions.
Study: 11300387
Drug: Combined femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined femoral and sciatic nerve block with bupivacaine 1 mg x kg(‐1) 7.5 mg x ml(‐1)
Study: 11300387
Drug: Combined femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined femoral and sciatic nerve block with ropivacaine 1 mg x kg(‐1) 7.5 mg x ml(‐1)
Study: 28062552
Drug: Double-dose IIV4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose IIV4 (0.5 mL, 15 µg per strain)
Study: 26582386
Drug: Comparison instruments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison instruments (EQ-5D-3 L; Edinburgh Postnatal Depression Scale; Satisfaction With Life Scale; State Trait Anxiety Inventory)
Study: 18308010
Drug: LRPT 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRPT 150 mg/day
Study: 19166443
Drug: ERN 1
Normalized name: QTERN 10mg-5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN 1 g
Study: 18308010
Drug: ERN 1
Normalized name: QTERN 10mg-5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN 1 g coadministered with LRPT 18.75, 37.5, 75, or 150 mg
Study: 11691520
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors or angiotensin receptor antagonists
Study: 11691520
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitors or angiotensin receptor antagonists
Study: 9145959
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycolic acid peels (20-70%) and cream containing 10% glycolic acid and 2% hydroquinone (Neostrata AHA Age Spot and Skin Lightening Gel)
Study: 7910999
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1.62 g EPA and 1.08 g DHA daily)
Study: 26400925
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) injections
Study: 25952818
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) injections
Study: 26299899
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy and nanocrystalline silver dressings
Study: 30990777
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) alone
Study: 21417561
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (EG) - 60 min supervised aerobic dance and strength training at least twice per week for a minimum of 12 weeks.
Study: 19139427
Drug: tremelimumab 10
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab 10 mg/kg once every month
Study: 19139427
Drug: tremelimumab 15
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab 15 mg/kg every 3 months
Study: 17198089
Drug: Chemoradioimmunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradioimmunotherapy with low-dose Interferon-alpha injection before therapy (arm A)
Study: 8050380
Drug: Clomipramine 75
Normalized name: clomipramine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 75 mg tablet (increased to 150 mg if necessary) for 8 weeks
Study: 11897643
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for 8 weeks
Study: 28295312
Drug: ADHD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD group (treated with stimulant medication)
Study: 28295312
Drug: ADHD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD group with Consistent or Inconsistent medication pattern
Study: 11010930
Drug: Elaidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elaidate (10 mg/kg body wt)
Study: 11010930
Drug: Linolenate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linolenate (10 mg/kg body wt)
Study: 8772622
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR 100 mg once daily
Study: 22417028
Drug: Perioperative beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative beta-blockers
Study: 22417028
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative beta-blockers (Control)
Study: 18560788
Drug: Resistant Starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant Starch with Wheat Bran (RS+WB) 2 x 15 g RS + 2 x 6 g WB
Study: 9794735
Drug: Atenolol (beta-blocker)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (beta-blocker)
Study: 12804926
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AR‐H040922 (13.3 microg/kg/min)
Study: 12804926
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose AR‐H040922 (6.7 microg/kg/min)
Study: 10821460
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin replacement therapy
Study: 10978944
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg loperamide
Study: 26930534
Drug: Lifestyle Balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle Balance treatment intervention (n = 60)
Study: 20676609
Drug: Cereboost™ (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereboost™ (100 mg)
Study: 20676609
Drug: Cereboost™ (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereboost™ (400 mg)
Study: 1447035
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (radiation)
Study: 25514077
Drug: Atomized buccal
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomized buccal midazolam (0.3 mg/kg)
Study: 10202575
Drug: CCK-4 bolus
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-4 bolus injection
Study: 25137428
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg)
Study: 31081404
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC, 50 mg)
Study: 28904053
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg olmesartan + 12.5 mg hydrochlorothiazide (OH)
Study: 28904053
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg telmisartan + 5 mg amlodipine (TA)
Study: 25907406
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBT-I), 5 sessions
Study: 15577584
Drug: 1110 MBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1110 MBq (30 mCi) 131I dose
Study: 15577584
Drug: 3700 MBq
Normalized name: dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3700 MBq (100 mCi) 131I dose
Study: 11912569
Drug: Continuation phase
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation phase (not specified which antidepressant continued)
Study: 3073870
Drug: 0.6 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg/day prednisolone for 3 weeks, then 0.3 mg/kg for a fourth week + 5 MU/m2 i.m. interferon for 12 weeks (5 days daily then three times a week)
Study: 3073870
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 5 MU/m2 i.m. interferon for 12 weeks (5 days daily then three times a week)
Study: 23588255
Drug: NSAID (Ibumetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (Ibumetin NYCOMED GmbH Plant Oranienburg Germany (600 mg) × 3/day/1 week)
Study: 20004356
Drug: Intravenous alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alpha-lipoic acid (ALA), administered daily for 3 weeks
Study: 10435201
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic olanzapine
Study: 8777099
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine 20 ml via a low thoracic extradural catheter and a diclofenac suppository (100 mg) given 30 min before incision (group 1)
Study: 29220623
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (n = 24)
Study: 25439419
Drug: IV succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV succinylcholine 0.3 mg/kg
Study: 25439419
Drug: IV succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV succinylcholine 0.6 mg/kg
Study: 25439419
Drug: IV succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV succinylcholine 1.0 mg/kg
Study: 23067904
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol administered before primary percutaneous coronary intervention (pPCI)
Study: 23067904
Drug: Oral metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoprolol initiated post-primary percutaneous coronary intervention (pPCI)
Study: 9761101
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol
Study: 20487410
Drug: Narrative exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative exposure therapy (NET) for 10 sessions
Study: 16608538
Drug: Adeli suit
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adeli suit treatment (AST)
Study: 10695095
Drug: HFA-BDP (354
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (354 patients; 75%) at half their current daily dose of CFC-BDP
Study: 8596569
Drug: Alprostadil (self-injection)
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil (self-injection)
Study: 1849160
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated hepatitis A virus vaccine (10(4.1), 10(5.2), 10(6.1), 10(7.3) TCID50)
Study: 28697863
Drug: Intra-articular TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular TXA (1 g intra-articularly and 50 mL intra-articular saline)
Study: 28697863
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1 g IV and 50 mL intra-articular saline)
Study: 28697863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g and 50 mL intra-articular saline)
Study: 31638960
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA
Study: 16556072
Drug: Standard first-line
Normalized name: Standard ANSI First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard first-line chemotherapy
Study: 11784964
Drug: Citicoline (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1.2 g/day for 4 days after surgery)
Study: 6131526
Drug: Flurazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam (15 mg)
Study: 6113127
Drug: Lormetazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (1 mg)
Study: 16937386
Drug: Family-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based therapy (FBT)
Study: 29314160
Drug: Systemic family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic family therapy (SyFT)
Study: 12917302
Drug: Methotrexate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15 mg per week)
Study: 21175564
Drug: Fumarates (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumarates (30 mg, followed by 120 mg according to a standard progressive dosage regimen)
Study: 14706912
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with estrogen and progestational agents
Study: 1478250
Drug: BIM 23014
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM 23014 (1000, 2000, and 3000 micrograms as a 24 h s.c. infusion)
Study: 1478250
Drug: BIM 23014
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM 23014 (2000 micrograms daily for 7 days as a continuous s.c. infusion)
Study: 31422039
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received donkey milk, Badanmu, Chamagu compound containing a variety of protein nutritional preparations 20g/d.
Study: 24655212
Drug: Separate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate group treatments of the overweight/obese parent and child (PC) - PC-1
Study: 24655212
Drug: Separate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate group treatments of the overweight/obese parent and child (PC) - PC-2
Study: 8977608
Drug: Intravenous doxapram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous doxapram
Study: 23743811
Drug: Chronic resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic resveratrol supplementation (75 mg daily for 6 weeks)
Study: 23743811
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of resveratrol (75 mg) after chronic supplementation
Study: 23512235
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone
Study: 22020609
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroid)
Study: 1421932
Drug: soy formula
Normalized name: Nursoy Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: soy formula (alone for seven days and then in combination with K‐Y for seven days)
Study: 28224644
Drug: Intratympanic normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic normal saline injection (ITNI)
Study: 26626581
Drug: AZD4901 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4901 40 mg twice daily (BID)
Study: 26626581
Drug: AZD4901 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4901 80 mg once daily (QD)
Study: 21182781
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravenous dexamethasone
Study: 20360317
Drug: Lithium (300-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (300-1200 mg/day)
Study: 18484901
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) for 8 weeks
Study: 17029334
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral pravastatin once daily for up to 14 days
Study: 12194927
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice a day for 4 days)
Study: 10604689
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg twice daily for 1 month
Study: 7577278
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg (group B)
Study: 1686130
Drug: Topical antipruritic
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical antipruritic corticosteroid
Study: 1686130
Drug: Clemastine (sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (sedative antihistamine)
Study: 1686130
Drug: Terfenadine (non-sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (non-sedative antihistamine)
Study: 7198413
Drug: Halothane 1.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane 1.25% followed by succinylcholine 2 mg/kg
Study: 31985516
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + Erlotinib (100 mg/d)
Study: 26743136
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg/die for 5 weeks
Study: 26743136
Drug: Danazol 100
Normalized name: danazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 100 mg/die for 5 weeks
Study: 19171708
Drug: Sorafenib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 600 mg twice daily (after progression)
Study: 12393357
Drug: Sufentanil (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (i.v. doses of 0.15 micro g kg(‐1))
Study: 9952092
Drug: SGB (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB (6 mL 1% lidocaine at C6)
Study: 9952092
Drug: Saline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (6 mL saline solution at C6)